hyoscine butylbromide oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   12 Trials   12 Trials   1304 News 


12345678910111213...2223»
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Aging-related impairment of neurogenic chloride secretion in human colon mucosa. (Pubmed Central) -  Apr 3, 2025   
    Significant impairments in neurogenic Cl- secretion occur in the aged colon, correlating with the degeneration of cholinergic and VIPergic nerves in the mucosa. This study could enhance our understanding of the pathophysiology of elderly constipation.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Preclinical, Journal:  Glycosyl terpenoid-rich fraction of TeMac (Pubmed Central) -  Apr 1, 2025   
    This study could enhance our understanding of the pathophysiology of elderly constipation. These findings suggest that the active ingredients in GT-TeMac
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Manipulation of artificial light environment improves tropane alkaloids content in Atropa belladonna L. (Pubmed Central) -  Mar 31, 2025   
    Metabolomic data confirmed that the levels of scopolamine, hyoscyamine, and their precursors increased under red-light...Moreover, red-light activated photosynthesis-related genes and transcription factors, indicating a coordinated regulatory relationship between light signal transduction and metabolic pathways. This study has preliminarily elucidated the potential mechanism by which red-light promotes the accumulation of TAs through enhancing nitrogen metabolism and precursor synthesis, providing a theoretical basis for improving the quality of A. belladonna and optimizing agricultural production.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Preclinical, Review, Journal:  Murine Non-Transgenic Models of Alzheimer's Disease Pathology: Focus on Risk Factors. (Pubmed Central) -  Mar 28, 2025   
    Thus, these models may serve as practical complementary tools for evaluating therapeutic and intervention strategies, since the primary AD risk factors are most frequently modeled. This review aims to critically assess the existing literature on AD non-transgenic models induced by streptozotocin, scopolamine, aging, mechanical stress, metals, and dietary patterns to enhance their application in AD research.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg., galantamine hydrobromide / Generic mfg.
    Journal:  Multi-target activity of ethanolic extract of Crinum woodrowii Baker for the treatment of Alzheimer's disease. (Pubmed Central) -  Mar 27, 2025   
    This review aims to critically assess the existing literature on AD non-transgenic models induced by streptozotocin, scopolamine, aging, mechanical stress, metals, and dietary patterns to enhance their application in AD research. Our findings suggested that the C. woodrowii extract has neuroprotective properties and ameliorates cognitive dysfunction and hence could be explored further as a potential neurotherapeutics for treating AD.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Preclinical, Journal:  1-Eplupinine enhances cognition and reduces inflammation in scopolamine-induced dementia model mice. (Pubmed Central) -  Mar 24, 2025   
    The result of the inflammation factors array detecting showed lower levels of GM-CSF, IFN-?, IL-2, and IL-23 significantly in the ELP (5?mg/kg) group, suggesting its potential anti-inflammatory properties for the dementia treatment. Therefore, ELP may serve as a promising treatment for early-stage dementia, offering cognitive improvement alongside anti-inflammatory neuroprotection.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg., rivastigmine / Generic mfg.
    Journal:  Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD. (Pubmed Central) -  Mar 16, 2025   
    In vivo investigations utilizing an AlCl3-induced zebrafish model of AD revealed that compound 6a significantly improved cognitive function, which was further supported by its ability to mitigate memory impairment induced by scopolamine. Overall, these results highlight compound 6a as a promising selective BuChE inhibitor with potential therapeutic implications for the treatment of Alzheimer's disease.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Is sleep affected after microgravity and hypergravity exposure? A pilot study. (Pubmed Central) -  Mar 16, 2025   
    Pre-existing sleep problems were related to sleep fragmentation and wake after sleep onset by a quadratic function such that participants with more sleep problems showed lower levels of sleep fragmentation and nighttime awakenings than those with few sleep problems. These novel findings, though preliminary, have important implications for future research, directed at prevention and treatment of sleep problems and their daytime consequences in situations of altered gravity, and possibly in the context of other daytime vestibular challenges as well.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg., rivastigmine / Generic mfg.
    SYNTHESIS AND STUDY OF SOME COUMARIN-OXADIAZOLE CONJUGATES AS POTENTIAL CANDIDATES FOR THE TREATMENT OF COGNITIVE DECLINE () -  Mar 10, 2025 - Abstract #ADPD2025ADPD_2458;    
    A series of 8 compounds have been synthesised and evaluated against behavioural alterations using step down passive avoidance protocol at a dose of 2 mg/kg using reference standard rivastigmine... Thus, PP-389 compound could be a promising lead structure that can be used for further development of agents with potential for cognition improvement.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    JANUS KINASE INHIBITOR CONFERS NEUROPROTECTION VIA MODULATING THE AMYLOIDOGENIC, NF-?B, AND NRF2 PATHWAYS AGAINST SCOPOLAMINE-INDUCED ALZHEIMER'S DISEASE IN RATS () -  Mar 10, 2025 - Abstract #ADPD2025ADPD_1946;    
    The rats received 2 mg/kg of scopolamine through an intraperitoneal injection every day for 14 days, which was followed by administration of JKI at doses of 0.45, 0.9, and 1.8 mg/kg and 5 mg/kg of donepezil orally as per group allocation, for the following 28 days while still receiving daily scopolamine injections. The study suggests that JKI may exhibit senomorphic potential via modification of the transcription factor- NF-?B and senescence-associated secretory phenotype and thus, confers neuroprotection via modulation of NF-?B and Nrf2 signalling axis in Alzheimer's disease.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    CHOLINERGIC SIGNALLING IS NECESSARY FOR AMYLOID REDUCTION INDUCED BY GAMMA STIMULATION_ () -  Mar 10, 2025 - Abstract #ADPD2025ADPD_1430;    
    GENUS also increased arterial diameter and pulsatility in saline- treated mice, but these effects were attenuated when cholinergic activity was blocked with scopolamine and mecamylamine... Our findings show that cholinergic signaling is essential for GENUS-inducedincreases in vasodilation, vasomotion, CSF influx, and amyloid clearance in a mouse model of amyloid pathology.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    THE APPLICATION OF LOCAL FIELD POTENTIAL IN PRECLINICAL ALZHEIMER () -  Mar 10, 2025 - Abstract #ADPD2025ADPD_1354;    
    Taken together, our results suggest that PAC decoupling could serve as a valuable biomarker for monitoring the progression of Alzheimer's disease (AD) in animal models. Given that PAC decoupling occurs significantly earlier than the onset of cognitive and behavioral impairments, it offers a promising new approach to predict clinical outcomes related to AD progression and therapeutic efficacy.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Use of deep learning-accelerated T2 TSE for prostate MRI: Comparison with and without hyoscine butylbromide admission. (Pubmed Central) -  Mar 9, 2025   
    In our study, cT2 sequences with HBB showed superior image quality and diagnostic confidence while the T2DL sequence offer promising potential for reducing MRI acquisition times and performed better in quantitative measures like SNR and CNR. Additional studies are required to evaluate further adjusted and developed DL applications for prostate MRI on upcoming scanner generations and to assess tumor detection rates.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Development of novel melatonin-isatin hybrids as multifunctional agents for Alzheimer's disease. (Pubmed Central) -  Mar 4, 2025   
    More importantly, compounds IM-5 and IM-10 could significantly ameliorate the memory impairment and cognition injury in scopolamine-induced mice...Molecular docking study further manifested that compounds IM-5 and IM-10 showed high hMAO-B inhibitory potency. In summary, all above results revealed compounds IM-5 and IM-10 might be promising multifunctional agents for AD treatment.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Scopolamine affects fear learning and social recognition in adult zebrafish. (Pubmed Central) -  Mar 1, 2025   
    In situ hybridization of c-fos mRNA showed that scopolamine decreased the neural activity of the telencephalic regions that are crucial for social, cognitive, and memory functions. Our results demonstrate the effects of scopolamine on fear learning and social recognition in adult zebrafish.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Review, Journal:  Choosing a drug to treat motion sickness. (Pubmed Central) -  Feb 25, 2025   
    Patients who suffer from motion sickness despite avoiding triggers and using behavioral modifications may benefit from individualized recommendations for pharmacologic therapy. Patients with refractory motion sickness can benefit from prophylactic drug therapy using first-generation antihistamines or scopolamine.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg., tramadol hydrochloride / Generic mfg., diclofenac/misoprostol / Generic mfg.
    Review, Journal:  Pharmacological and non-pharmacological interventions for pain control in outpatient hysteroscopy: A systematic review. (Pubmed Central) -  Feb 23, 2025   
    This study highlights potential use of both pharmacological and non-pharmacological methods as safe and effective forms of analgesia for OPH. We hope the results of this systematic review will help improve clinical practice and assist with developing future pain management protocols for OPH while also highlighting areas of interest for future research.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Preclinical, Journal:  Enhanced Cognitive and Memory Functions via Gold Nanoparticle-Mediated Delivery of Afzelin through Synaptic Modulation Pathways in Alzheimer's Disease Mouse Models. (Pubmed Central) -  Feb 20, 2025   
    AuNP-afzelin also performed superior neuroprotective effects of rescuing mature neuronal cells and recovered cholinergic dysfunction compared to afzelin alone, according to further investigations of BDNF-pCREB-pAkt signaling, long-term potentiation, and doublecortin (DCX) expression in the hippocampus. This study highlights the potential of afzelin with gold nanoparticles as a promising therapeutic approach for mitigating cognitive impairments associated with neurodegenerative diseases and offers a new avenue for future research and drug development.
  • ||||||||||  Preclinical, Journal:  Exploring the Antiemetic Potential of Caffeic Acid: A Combined In (Pubmed Central) -  Feb 18, 2025   
    This research indicated that CAF has mild antiemetic properties by interacting with the D2, 5TH3, and M5 receptors. Therefore, several preclinical and clinical studies are necessary to assess the effectiveness and safety profile of this food ingredient.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Effect of muscarinic blockade on the speed of attention shifting, read-out delays and learning. (Pubmed Central) -  Feb 15, 2025   
    In study 1, each subject participated in 2 sessions (scopolamine/placebo), whereby the order of drug intake was counterbalanced across subjects, and subjects were blinded to conditions...Additionally, blockade of muscarinic receptors immediately after the first session reduced learning dependent improvement of read-out delays. These results demonstrate that muscarinic receptors play an important in detecting cues, and fast read-out of cued information, and they contribute to the learning thereof.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Effects of TGF-?1 on A?-40 and ?- ?- ? Secretase Expression in Hippocampus and Prefrontal Cortex in Experimental Alzheimer's Disease. (Pubmed Central) -  Feb 13, 2025   
    It was thought that TGF-?1 might have a therapeutic effect on Alzheimer's disease by increasing memory performance and preventing A?-40 accumulation in the AD-like model induced by Scopolamine and also, may be effective preventing neuronal damage by down-regulating caspase-3 expression. When all the findings evaluated together, it was concluded that TGF-?1 could be evaluated as a therapeutic agent in Alzheimer's disease.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Sweroside Modulates Oxidative Stress and Neuroplasticity-Related Gene Expression in Scopolamine-Treated Zebrafish. (Pubmed Central) -  Feb 12, 2025   
    When all the findings evaluated together, it was concluded that TGF-?1 could be evaluated as a therapeutic agent in Alzheimer's disease. Overall, our findings suggested that Swe has a positive role in the cholinergic system activity and brain antioxidant status and showed for the first time that it can restore the downregulated expression of bdnf, npy, egr1, nfr2a, and creb1 genes in the brain of the Sco-induced zebrafish model.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Molecular mechanisms that regulate scopolamine effects on inducible fish antipredation responses in Daphnia magna. (Pubmed Central) -  Jan 30, 2025   
    Most enriched metabolic routes were related with neurological pathways and regulation of cell proliferation/differentiation. Our results indicate that fish kairomones and scopolamine deregulate not only neurological signaling pathways but also cell differentiation and proliferation pathways, which are linked to the observed behavioral responses as well as the developmental, morphological, and reproductive effects.